Royalty Pharma plc (NASDAQ:RPRX) Q4 2021 Earnings Conference Call February 15, 2022 8:00 AM ET
Company Participants
George Grofik – Senior Vice President, Head-Investor Relations and Communications
Pablo Legorreta – Founder and Chief Executive Officer
Jim Reddoch – Executive Vice President, Co-Head-Research and Investments and Chief Scientific Officer
Marshall Urist – Executive Vice President, Co-Head of Research and Investments
Terry Coyne – Executive Vice President and Chief Financial Officer
Conference Call Participants
Geoff Meacham – Bank of America
Mike DiFiore – Evercore ISI
Chris Schott – J.P. Morgan
Steve Scala – Cowen
Charlie Chen – Morgan Stanley
Greg Fraser – Truist Securities
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Fourth Quarter Earnings Conference Call. I would now like to turn the call over to George Grofik, Senior Vice President, Head of Investor Relations and Communications. Please go ahead, sir.
George Grofik
Thank you, operator. And good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's fourth quarter and full year 2021 results. You can find the press release with our earnings results and slides to this call on the Investors page of our website at royaltypharma.com.
Moving to Slide 3. I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from these statements. I refer you to our 10-K on file with the SEC for a description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma and we assume no obligation to update any such forward-looking statements.
Non-GAAP financial measures will be used to help you understand our financial performance. The GAAP to non-GAAP reconciliations are
- Read more current RPRX analysis and news
- View all earnings call transcripts